Robert A. Ingram

General Partner

Mr. Robert Ingram, also known as Bob, is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief ExecutiveOfficer and Chairman of Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram is Chairman of the boards of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, Viamet Pharmaceuticals Inc., a private company focused on anti-infective research, and BioCryst Pharmaceuticals, Inc.He also serves as the Lead Director on the board of Cree, Inc. In 2013, Bob received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.

At the request of US President George H.W. Bush, Bob formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In 2014, Bob received the North Carolina Award, the highest civilian honor the state can bestow on an individual. He received the award for public service. He serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GlaxoSmithKline Foundation.

Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

COMMUNITY AND BOARD ENGAGEMENTS:

Bob is a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation.

BACK TO TEAM